The resultsadd to evidence for the potential of ctDNA tumor fraction as a new monitoring tool that could allow clinical researchers to detect tumor progression and change treatment strategies earlier than through current methods.
Immunotherapy has transformed cancer treatment in just a few years, and studies presented at the AACR Annual Meeting show how proteomics will further unlock immunotherapy’s potential and help bring the next generation of therapies to market.
DNA methylation analysis in the blood, powered by advances in wet-lab chemistry and bioinformatics, has enabled the use of epigenomic profiling to enhance the sensitivity of liquid biopsy, providing a deeper understanding of tumor biology and expanding the promise of precision oncology beyond what genomic information can offer.
In February 2023, Seegene met with Marta del Pino at Eurogin, the leading international conference focused on human papillomavirus (HPV) and associated cancers, to discuss the value of HPV testing and genotyping in the new cervical cancer screening paradigm.
In the wake of a transformational period for bladder cancer treatment, the time is right to harness integrated care coordination and precision medicine in order to optimize patient outcomes across the disease continuum.